
David E Connor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2204297/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Building platelet phenotypes: Diaphanous-related formin 1 (DIAPH1)-related disorder. Platelets, 2022, 33, 432-442.	2.3	3
2	Professor Kenneth Arthur Myers MS, FRACS, FACS, DDU (Vasc), 14th February 1935–3rd March 2021. Phlebology, 2022, 37, 72-74.	1.2	0
3	The utility of flow cytometric platelet forward scatter as an alternative to mean platelet volume. Platelets, 2022, , 1-7.	2.3	2
4	Chronic venous disease, platelet and haemostatic abnormalities contribute to the pathogenesis of pigmented purpuric dermatoses. Phlebology, 2022, 37, 348-360.	1.2	3
5	Treatment of venous malformations with tumescent-assisted sclero-embolic and ablative lasers (SEALs): Safe and effective long-term outcomes. Phlebology, 2022, , 026835552210800.	1.2	3
6	A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Advances, 2022, 6, 3494-3506.	5.2	17
7	Skin necrosis following sclerotherapy. Part 1: Differential diagnosis based on classification of pathogenic mechanisms. Phlebology, 2022, 37, 409-424.	1.2	2
8	A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia. Pathology, 2022, 54, 746-754.	0.6	2
9	Foam bubble size is significantly influenced by sclerosant concentration for polidocanol but not sodium tetradecyl sulphate. Phlebology, 2021, 36, 576-587.	1.2	1
10	LIPIODOL reduces the lytic activity of detergent sclerosants <i>in vitro</i> . Phlebology, 2021, 36, 771-778.	1.2	0
11	Ex Vivo Assessment of Different Oral Anticoagulant Regimens on Pump Thrombosis in a HeartWare Ventricular Assist Device. Circulation: Heart Failure, 2021, 14, e007231.	3.9	1
12	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	3.8	20
13	Kenneth Arthur Myers (1935-2021). Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 1345-1346.	1.6	0
14	Deep vein sclerosis following sclerotherapy: Ultrasonic and <scp>d</scp> -dimer criteria. Phlebology, 2020, 35, 325-336.	1.2	11
15	Cyanoacrylate closure for peripheral veins: Consensus document of the Australasian College of Phlebology. Phlebology, 2020, 35, 153-175.	1.2	34
16	Circulating blood cells influence the fibrinolytic capacity of clots generated in the presence of detergent sclerosants. Phlebology, 2020, 35, 273-280.	1.2	0
17	An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology, 2020, 52, 243-255.	0.6	15
18	The clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy – A case series and review of the literature. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 106-110.	2.3	4

DAVID E CONNOR

#	Article	IF	CITATIONS
19	Sirolimus and propranolol inhibit endothelial proliferation while detergent sclerosants induce endothelial activation, microparticle release and apoptosis in vitro. Phlebology, 2020, 35, 566-575.	1.2	4
20	Angioscopy: Direct visualization of chronic venous occlusion, May-Thurner syndrome, and other applications in phlebology. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 870-881.	1.6	2
21	Two layers of graduated compression stockings can reduce healthy saphenous vein diameters in the standing position. Phlebology, 2019, 34, 559-565.	1.2	2
22	Telangiectatic Matting is Associated with Hypersensitivity and a Bleeding Tendency. European Journal of Vascular and Endovascular Surgery, 2018, 55, 554-559.	1.5	5
23	Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. Journal of Thrombosis and Haemostasis, 2018, 16, 1236-1245.	3.8	130
24	Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. Journal of Thrombosis and Haemostasis, 2018, 16, 1198-1210.	3.8	38
25	Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous) Tj ETQq1 1 0.784:	314 rgBT /(1.2	Overlock 10 Ti
26	Higher Soluble Thrombomodulin and Angiogenic Markers in LVAD Supported Patients Associate with Arteriovenous Malformation and Non-Surgical Bleeding. Journal of Heart and Lung Transplantation, 2018, 37, S159-S160.	0.6	1
27	Flow Cytometry Protocols for Assessment of Platelet Function in Whole Blood. Methods in Molecular Biology, 2017, 1646, 369-389.	0.9	24
28	Generation of sclerosant foams by mechanical methods increases the foam temperature. Phlebology, 2017, 32, 501-505.	1.2	2
29	Detergent Sclerosants Stimulate Leukocyte Apoptosis and Oncosis. European Journal of Vascular and Endovascular Surgery, 2016, 51, 846-856.	1.5	9
30	Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease. Platelets, 2016, 27, 805-811.	2.3	19
31	Detergent sclerosants at sub-lytic concentrations induce endothelial cell apoptosis through a caspase dependent pathway. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 836-845.	4.9	17
32	Morphological changes in vascular and circulating blood cells following exposure to detergent sclerosants. Phlebology, 2016, 31, 177-191.	1.2	6
33	Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2016, 35, 743-751.	0.6	38
34	Detergent Sclerosants are Deactivated and Consumed by Circulating Blood Cells. European Journal of Vascular and Endovascular Surgery, 2015, 49, 426-431.	1.5	34
35	Basic physiochemical and rheological properties of detergent sclerosants. Phlebology, 2015, 30, 339-349.	1.2	22
36	Infusion of foam sclerosants results in a distance-dependent procoagulant activity, haemoconcentration and elevation of D-dimer levels. Phlebology, 2014, 29, 677-687.	1.2	9

DAVID E CONNOR

#	Article	lF	CITATIONS
37	Low-concentration detergent sclerosants stimulate white blood cells and release proinflammatory and proangiogenic cytokines inÂvitro. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2014, 2, 433-440.	1.6	4
38	Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders. Thrombosis Research, 2013, 132, 572-577.	1.7	25
39	Sclerosant Foam Structure and Stability is Strongly Influenced by Liquid Air Fraction. European Journal of Vascular and Endovascular Surgery, 2013, 46, 488-494.	1.5	36
40	Foam Sclerosants are More Stable at Lower Temperatures. European Journal of Vascular and Endovascular Surgery, 2013, 46, 593-599.	1.5	30
41	Low Concentration Detergent Sclerosants Induce Platelet Activation but Inhibit Aggregation due to Suppression of GPIIb/IIIa Activation in vitro. Thrombosis Research, 2012, 130, 472-478.	1.7	21
42	Cyclic thrombocytopenia associated with marked rebound thrombocytosis and fluctuating levels of endogenous thrombopoietin and reticulated platelets: A case report. American Journal of Hematology, 2012, 87, 120-122.	4.1	10
43	The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thrombosis and Haemostasis, 2010, 103, 1044-1052.	3.4	263
44	Generation and characterization of mice with null mutation of the chloride intracellular channel 1 gene. Genesis, 2010, 48, NA-NA.	1.6	23
45	Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagulation and Fibrinolysis, 2009, 20, 558-564.	1.0	54
46	The Lytic Effects of Detergent Sclerosants on Erythrocytes, Platelets, Endothelial Cells and Microparticles are Attenuated by Albumin and other Plasma Components in Vitro. European Journal of Vascular and Endovascular Surgery, 2008, 36, 216-223.	1.5	91
47	Nucleus Pulposus Cellular Longevity by Telomerase Gene Therapy. Spine, 2007, 32, 1188-1196.	2.0	38
48	Platelet activation in acute pulmonary embolism. Journal of Thrombosis and Haemostasis, 2007, 5, 918-924.	3.8	63
49	In Vitro Effects of Detergent Sclerosants on Coagulation, Platelets and Microparticles. European Journal of Vascular and Endovascular Surgery, 2007, 34, 731-740.	1.5	62
50	Letter: A Convenient Source of Carbon Dioxide for Sclerosant Foams. Dermatologic Surgery, 2006, 32, 1533-1534.	0.8	4
51	Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: a pilot study. Blood Coagulation and Fibrinolysis, 2005, 16, 375-379.	1.0	10
52	Control of glycolysis in mature boar spermatozoa: effect of pH in vitro. Reproduction, Fertility and Development, 2004, 16, 319.	0.4	9
53	A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagulation and Fibrinolysis, 2003, 14, 773-779.	1.0	45
54	Fructose metabolism by mature boar spermatozoa. Reproduction, Fertility and Development, 2000, 12, 355.	0.4	23

#	Article	IF	CITATIONS
55	Computational Fluid Dynamics of Liquid and Foam Sclerosant Injection in a Vein Model. Applied Mechanics and Materials, 0, 553, 293-298.	0.2	5